Literature DB >> 10594326

On the mechanism underlying calcein-induced cytotoxicity.

G Liminga1, B Jonsson, P Nygren, R Larsson.   

Abstract

The cellular pharmacology of calcein acetoxymethyl ester (calcein/AM)-induced cytotoxicity was investigated in human tumor cell lines in order to identify tentative mechanisms of action. The activity profile in 10 cell lines with known mechanisms of resistance was compared with the activity profiles of standard drugs and experimental substances. The activity of calcein correlated with that of different topo II inhibitor/intercalating compounds and mitochondrial accumulating compounds, such as Rhodamine 123, Mito Fluor Green and Acridine Orange-10. Using U-937 GTB as a model cell line, calcein was found to distribute throughout the whole cell, nuclei and mitochondria included. In addition, studies of mitochondrial dehydrogenase activity and extracellular acidification rate showed an almost complete lack of dehydrogenase activity and extracellular acidification at 12 and 24 h, respectively. The results indicate that calcein/AM may induce cytotoxicity through interference with both mitochondrial and nuclear DNA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594326     DOI: 10.1016/s0014-2999(99)00655-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.

Authors:  Miriam Zanuy; Antonio Ramos-Montoya; Oscar Villacañas; Nuria Canela; Anibal Miranda; Esther Aguilar; Neus Agell; Oriol Bachs; Jaime Rubio-Martinez; Maria Dolors Pujol; Wai-Nang P Lee; Silvia Marin; Marta Cascante
Journal:  Metabolomics       Date:  2011-07-08       Impact factor: 4.290

2.  Comparison of different live/dead stainings for detection and quantification of adherent microorganisms in the initial oral biofilm.

Authors:  P N Tawakoli; A Al-Ahmad; W Hoth-Hannig; M Hannig; C Hannig
Journal:  Clin Oral Investig       Date:  2012-07-21       Impact factor: 3.573

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.